– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
No appointments. No pressure. No limits. Just 24/7 access to windows, doors, and baths—on your terms.
WESTLAKE, Ohio, July 16, 2025 /PRNewswire/ -- Window &...
The collaboration aims to deploy LiDAR-camera perception nodes for perimeter and area monitoring across India unlocking real-time, edge-native intelligence for critical infrastructure
NEW DELHI, July...
London, July 15, 2025 (GLOBE NEWSWIRE) -- SIGMA AI, an innovative fintech company specialising in real-time data and AI-driven insights, today announced a minority investment by Trading Technologies, International Inc. (TT), a global capital markets technology platform services provider.